期刊论文详细信息
BMC Medical Genomics
Systematic genomic identification of colorectal cancer genes delineating advanced from early clinical stage and metastasis
Hanlee P Ji1  Patrick Flaherty3  HoJoon Lee2 
[1] Stanford Genome Technology Center, Stanford University, Palo Alto, CA 94304, USA;Division of Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA;Department of Biomedical Engineering, Worcester Polytechnic Institute, Worcester, MA 01605, USA
关键词: Metastasis;    Clinical stage;    Genetics;    Genomics;    Colorectal cancer;   
Others  :  1091230
DOI  :  10.1186/1755-8794-6-54
 received in 2013-09-19, accepted in 2013-11-27,  发布年份 2013
PDF
【 摘 要 】

Background

Colorectal cancer is the third leading cause of cancer deaths in the United States. The initial assessment of colorectal cancer involves clinical staging that takes into account the extent of primary tumor invasion, determining the number of lymph nodes with metastatic cancer and the identification of metastatic sites in other organs. Advanced clinical stage indicates metastatic cancer, either in regional lymph nodes or in distant organs. While the genomic and genetic basis of colorectal cancer has been elucidated to some degree, less is known about the identity of specific cancer genes that are associated with advanced clinical stage and metastasis.

Methods

We compiled multiple genomic data types (mutations, copy number alterations, gene expression and methylation status) as well as clinical meta-data from The Cancer Genome Atlas (TCGA). We used an elastic-net regularized regression method on the combined genomic data to identify genetic aberrations and their associated cancer genes that are indicators of clinical stage. We ranked candidate genes by their regression coefficient and level of support from multiple assay modalities.

Results

A fit of the elastic-net regularized regression to 197 samples and integrated analysis of four genomic platforms identified the set of top gene predictors of advanced clinical stage, including: WRN, SYK, DDX5 and ADRA2C. These genetic features were identified robustly in bootstrap resampling analysis.

Conclusions

We conducted an analysis integrating multiple genomic features including mutations, copy number alterations, gene expression and methylation. This integrated approach in which one considers all of these genomic features performs better than any individual genomic assay. We identified multiple genes that robustly delineate advanced clinical stage, suggesting their possible role in colorectal cancer metastatic progression.

【 授权许可】

   
2013 Lee et al.; licensee BioMed Central Ltd.

【 预 览 】
附件列表
Files Size Format View
20150128170426519.pdf 918KB PDF download
Figure 7. 28KB Image download
Figure 6. 76KB Image download
Figure 5. 25KB Image download
Figure 4. 36KB Image download
Figure 3. 60KB Image download
Figure 2. 38KB Image download
Figure 1. 40KB Image download
【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】
  • [1]Siegel R, Naishadham D, Jemal A: Cancer Statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
  • [2]Vogelstein B, Kinzler KW: Cancer genes and the pathways they control. Nat Med 2004, 10:789-799.
  • [3]Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JKV, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PVK, et al.: The genomic landscapes of human breast and colorectal cancers. Science 2007, 318:1108-1113.
  • [4]Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JKV, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE: The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274.
  • [5]Fearon ER: Molecular genetics of colorectal cancer. Annu Rev Pathol 2011, 6:479-507.
  • [6]Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
  • [7]Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW: Cancer genome landscapes. Science 2013, 339:1546-1558.
  • [8]Forbes S a, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, Teague JW, Campbell PJ, Stratton MR, Futreal PA: COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res 2011, 39(Database issue):D945-D950.
  • [9]Bienz M, Clevers H: Linking colorectal cancer to Wnt signaling. Cell 2000, 103:311-320.
  • [10]Shirasawa S, Furuse M, Yokoyama N, Sasazuki T: Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993, 260:85-88.
  • [11]Pasche B, Kaklamani V, Hou N, Young T, Rademaker A, Peterlongo P, Ellis N, Offit K, Caldes T, Reiss M, Zheng T: TGFBR1*6A and cancer: a meta-analysis of 12 case–control studies. J Clin Oncol 2004, 22:756-758.
  • [12]Mutch MG: Molecular profiling and risk stratification of adenocarcinoma of the colon. J Surg Oncol 2007, 96:693-703.
  • [13]Muzny DM, Bainbridge MN, Chang K, Dinh HH, Drummond J a, Fowler G, Kovar CL, Lewis LR, Morgan MB, Newsham IF, Reid JG, Santibanez J, Shinbrot E, Trevino LR, Wu YQ, Wang M, Gunaratne P, Donehower L a, Creighton CJ, Wheeler D a, Gibbs R a, Lawrence MS, Voet D, Jing R, Cibulskis K, Sivachenko A, Stojanov P, McKenna A, Lander ES, Gabriel S, et al.: Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337.
  • [14]Shen R, Olshen AB, Ladanyi M: Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis. Bioinformatics 2009, 25:2906-2912.
  • [15]Vucic EA, Thu KL, Robison K, Rybaczyk LA, Chari R, Alvarez CE, Lam WL: Translating cancer “omics” to improved outcomes. Genome Res 2012, 22:188-195.
  • [16]Chin L, Hahn WC, Getz G, Meyerson M: Making sense of cancer genomic data. Genes Dev 2011, 25:534-555.
  • [17]Goldman M, Craft B, Swatloski T, Ellrott K, Cline M, Diekhans M, Ma S, Wilks C, Stuart J, Haussler D, Zhu J: The UCSC cancer genomics browser: update 2013. Nucleic Acids Res 2013, 41(Database issue):D949-D954.
  • [18]Woerner SM, Yuan YP, Benner A, Korff S, von Knebel Doeberitz M, Bork P: SelTarbase, a database of human mononucleotide-microsatellite mutations and their potential impact to tumorigenesis and immunology. Nucleic Acids Res 2010, 38(Database issue):D682-D689.
  • [19]Vilar E, Gruber SB: Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol 2010, 7:153-162.
  • [20]Gray K, Daugherty LC, Gordon SM, Seal RL, Wright MW, Bruford E: Genenames.org: the HGNC resources in 2013. Nucleic Acids Res 2013, 41(Database issue):D545-D552.
  • [21]I. T. Jolliffe: Principal Component Analysis (Springer Series in Statistics). 2nd edition. New York: Springer; 2002.
  • [22]Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001, 98:5116-5121.
  • [23]Zou H, Hastie T: Regularization and variable selection via the elastic net. J R Stat Soc Ser B (Statistical Methodol 2005, 67:301-320.
  • [24]Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo W-L, Lapuk A, Neve RM, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, Kingsley C, Dairkee S, Meng Z, Chew K, Pinkel D, Jain A, Ljung BM, Esserman L, Albertson DG, Waldman FM, Gray JW: Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006, 10:529-541.
  • [25]Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, Langerod A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Borresen-Dale A-L, Brenton JD, Tavare S, Caldas C, et al.: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352.
  • [26]Shen L, Toyota M, Kondo Y, Lin E, Zhang L, Guo Y, Hernandez NS, Chen X, Ahmed S, Konishi K, Hamilton SR, Issa J-PJ: Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A 2007, 104:18654-18659.
  • [27]Mo Q, Wang S, Seshan VE, Olshen AB, Schultz N, Sander C, Powers RS, Ladanyi M, Shen R: Pattern discovery and cancer gene identification in integrated cancer genomic data. Proc Natl Acad Sci U S A 2013, 110:4245-4250.
  • [28]Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, Sachidanandam R, Sørlie T, Wärnberg F, Haakensen VD, Helland Å, Naume B, Perou CM, Haussler D, Troyanskaya OG, Børresen-Dale A-L: Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci U S A 2012, 109:2802-2807.
  • [29]Ernst J, Plasterer HL, Simon I, Bar-Joseph Z: Integrating multiple evidence sources to predict transcription factor binding in the human genome. Genome Res 2010, 20:526-536.
  • [30]Davison AC, Hinkley DV: Bootstrap Methods and Their Application. Cambridge: Cambridge University Press; 1997.
  • [31]Cancer T, Atlas G: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068.
  • [32]Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD: IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009, 360:765-773.
  • [33]Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B: Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995, 268:1336-1338.
  • [34]Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, Jessup JM, Kolodner R: Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997, 57:808-811.
  • [35]Chughtai SA, Crundwell MC, Cruickshank NR, Affie E, Armstrong S, Knowles MA, Takle LA, Kuo M, Khan N, Phillips SM, Neoptolemos JP, Morton DG: Two novel regions of interstitial deletion on chromosome 8p in colorectal cancer. Oncogene 1999, 18:657-665.
  • [36]Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Liu Z, Yamamoto H, Loda M, Fuchs CS, Ogino S: WRN promoter methylation possibly connects mucinous differentiation, microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod Pathol 2008, 21:150-158.
  • [37]Agrelo R, Cheng W-H, Setien F, Ropero S, Espada J, Fraga MF, Herranz M, Paz MF, Sanchez-Cespedes M, Artiga MJ, Guerrero D, Castells A, von Kobbe C, Bohr VA, Esteller M: Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc Natl Acad Sci U S A 2006, 103:8822-8827.
  • [38]Coopman PJ, Do MT, Barth M, Bowden ET, Hayes AJ, Basyuk E, Blancato JK, Vezza PR, McLeskey SW, Mangeat PH, Mueller SC: The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. Nature 2000, 406:742-747.
  • [39]Kanaan Z, Rai SN, Eichenberger MR, Roberts H, Keskey B, Pan J, Galandiuk S: Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann Surg 2012, 256:544-551.
  • [40]Si M-L, Zhu S, Wu H, Lu Z, Wu F: Mo Y-Y: miR-21-mediated tumor growth. Oncogene 2007, 26:2799-2803.
  • [41]Yamamoto K, Imakiire A, Miyagawa N, Kasahara T: A report of two cases of Werner’ s syndrome and review of the literature.. 2003, 11:224-233.
  • [42]Hickson ID: RecQ helicases: Caretakers of the genome. Nat Rev Cancer 2003, 3:169-178.
  • [43]Epstein CJ, Martin GM, Schultz AL, Motulsky AG: Werner’s syndrome a review of its symptomatology, natural history, pathologic features, genetics and relationship to the natural aging process. Medicine (Baltimore) 1966, 45:177-221.
  • [44]Solimini NL, Xu Q, Mermel CH, Liang AC, Schlabach MR, Luo J, Burrows AE, Anselmo AN, Bredemeyer AL, Li MZ, Beroukhim R, Meyerson M, Elledge SJ: Recurrent hemizygous deletions in cancers may optimize proliferative potential. Science 2012, 337:104-109.
  • [45]Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, Hammond MEH, Henson DE, Hutter RVP, Nagle RB, Nielsen ML, Sargent DJ, Taylor CR, Welton M, Willett C: Prognostic factors in colorectal cancer. Arch Pathol Lab Med 2000, 124:979-994.
  • [46]Shibayama M, Maak M, Nitsche U, Gotoh K, Rosenberg R, Janssen K-P: Prediction of metastasis and recurrence in colorectal cancer based on gene expression analysis: Ready for the clinic? Cancers (Basel) 2011, 3:2858-2869.
  文献评价指标  
  下载次数:24次 浏览次数:9次